hotspot -WSS

hotspot

author：focus 2025-09-27 14:10:36 - browse：491

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： The new shift in health care is toward less care

Wikipedia

WSS

The new shift in health care is toward less care

Removing probiotics from the NICU could threaten preemies' health

10 million people disenrolled from Medicaid over past six months

Free speech concerns arise in wake of journal editor Eisen's firing

HPV vaccine, cervical cancer study delivers historic results

Microsoft launches AI tool for clinical documentation through Epic

explore

hotspot

hotspot

Hollywood unions extend contract negotiations for actors

Extreme heat events are a public health emergency

Peter Hotez and the public health issue of online harassment

The new shift in health care is toward less care

Bright Health sells Medicare Advantage business to Molina

High breast density mammograms need follow

As demand for Covid shots wanes, Moderna seeks its next success

Immunocompromised patients offer clues on chronic Covid

Medical records are filled with copy

What causes osteoarthritis? Researchers study link to brain protein

hotspot

CVS is on a mission to consolidate health care. Will it work?

FDA endorses new sterilization method for medical devices

Study: New antibiotic targets gonorrhea as well as last existing drug

Removing probiotics from the NICU could threaten preemies' health

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

HPV vaccine, cervical cancer study delivers historic results

Wikipedia

leisure time

hotspot

explore